MRNA Stock Recent News

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats CAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years.

Moderna is testing a norovirus vaccine in a phase three trial, with results available as soon as this year. Norovirus cases are on the rise this winter, with outbreaks already up more than 30% by December, per data from the Centers for Disease Control and Prevention.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Moderna stock surged Wednesday after Oracle Chairman Larry Ellison praised the potential of AI in developing medicines. The post Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines appeared first on Investor's Business Daily.

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness Innovations, has approved the progression of a US$4.8 million (AU$7.2 million) program to develop heat-stable, dried-formulation mRNA vaccines delivered using Vaxxas' needle-free high-density microarray patch (HD-MAP). The approval follows pro.

Biotechnology company Moderna Inc. NASDAQ: MRNA gained the spotlight in the medical sector as a leader in the race toward a COVID-19 vaccine. Its messenger RNA (mRNA) technology garnered acclaim as a next-generation therapy.

Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.

Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.

Shares of Moderna (MRNA) took off Tuesday when the biotech firm announced that the U.S. government has awarded it more than a half a billion dollars to develop a vaccine that can be used against bird flu.

Moderna Inc (NASDAQ:MRNA) stock is surging today, up 8.7% at $37.02 at last glance, after the vaccine maker was awarded $590 million from the U.S. Health and Human Services Department to speed up the development of its bird flu vaccine, as the virus spreads rapidly throughout the country.